Vir Biotechnology gets in Exclusive Worldwide License Agreement with Sanofi for Multiple Clinical-Stage T-cell Engagers August 7, 2024
Immunome acquired worldwide, exclusive rights to a panel of antibodies from Nectin Therapeutics, Bluefin Biomedicine, and from OncoResponse July 30, 2024
NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production July 30, 2024
Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline July 23, 2024
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline July 23, 2024
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations for Evaluating ORIC-944 + AR Inhibitors for the Treatment of Prostate Cancer July 23, 2024
Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations July 23, 2024
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors July 23, 2024
CatalYm Announces New Financing of $150M to Support Broad Ph 2b Development Program for Visugromab July 23, 2024
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 + KEYTRUDA in Patients with SMARCA4-Mutated Cancers July 17, 2024
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for novel ADC July 17, 2024
Nona Biosciences Enters into Collaboration Agreement with Alaya.bio to Advance CAR-T Cell Therapy July 17, 2024
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 anti-VISTA Checkpoint Inhibitor July 17, 2024
ReEngage Therapeutics Announces Research Agreement to Accelerate Development of ACSS2 Inhibitors as Cancer Therapies July 17, 2024
Eisai and BMS end global strategic collaboration for the co-development and co-commercialization of farletuzumab ecteribulin; now all rights with Eisai July 9, 2024
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor July 9, 2024
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced NET based on positive CABINET Ph 3 trial July 9, 2024
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat for the Treatment of Metastatic CRPC July 9, 2024
Ubix Therapeutics and Yuhan Announce Exclusive License Agreement for UBX-103 for Treatment of Metastatic CRPC July 9, 2024
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 July 9, 2024
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies July 1, 2024
